News Specialty meds lift GSK's outlook in Walmsley's swan song Emma Walmsley's last set of financial results as GSK's chief executive has gone swimmingly, allowing the company to raise its 2025 forecasts.
News Novartis' new drugs outweigh Entresto decline in Q3 Now feeling the impact of generic competition on its top product Entresto in the US, Novartis is still looking for pipeline-building deals, says CEO.
News AZ, Organon fall foul of UK's code on pharma promotion AstraZeneca and Organon have breached the UK pharma industry's code of practice with promotions for an asthma drug and a contraceptive implant.
News Merck looking to rare disease deals to build health momentum Germany's Merck KGaA is looking at making further acquisitions to boost its business, with a focus on life sciences and rare diseases.
News J&J streamlines with plan to hive off orthopaedics unit Johnson & Johnson has said it wants to spin off its orthopaedics division as part of an effort to redirect its business towards higher-growth areas.
News Indivior stops Opvee promotion in New York after settlement Indivior has agreed to halt all marketing of its opioid overdose drug Opvee in New York after being rapped for mispromoting it to health officials.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.